Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7653649 | 0.89 | KMO (0.44) | MAOAMAOBKMOEGFRERBB2 | |
| SCHEMBL7425784 | 0.88 | KMO (0.60) | MAOAMAOBKMOEGFRERBB2 | |
| SCHEMBL7426302 | 0.88 | EGFR (0.45) | MAOAMAOBGAAEGFRERBB2 | |
| SCHEMBL8684577 | 0.88 | KMO (0.43) | MAOAMAOBKMOEGFRERBB2 | |
| SCHEMBL4957912 | 0.84 | HTR2A (0.46) | MAOAMAOBKMOEGFRERBB2 | |
| SCHEMBL904672 | 0.84 | MAPT (0.48) | EGFRERBB2ALDH1A1KDM4ECA12 | |
| SCHEMBL4959328 | 0.83 | MAOA (0.43) | MAOAMAOBKMOGAAEGFR | |
| SCHEMBL7428104 | 0.82 | PLA2G4A (0.46) | MAOAMAOBEGFRERBB2ALDH1A1 | |
| SCHEMBL8684617 | 0.82 | MAOA (0.43) | MAOAMAOBKMOEGFRERBB2 | |
| Hydrochloric Acid SCHEMBL8683583 | 0.81 | MAOA (0.42) | MAOAMAOBKMOEGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6489333-B2 | HETEROCYCLIC COMPOUNDS CONTAINING A GUANIDINE MIMIC, FOR INHIBITION OF CELL ADHESION, TREATMENT OF ANGIOGENESIS DISORDERS, INFLAMMATION, CANCER METASTASIS, DIABETIC RETINOPATHY, THROMBOSIS, RESTENOSIS, MACULAR DEGENERATION | BRISTOL - MEYERS SQUIBB PHARMA COMPANY | 2002-12-03 | — | — | US | disclosed |
| US-20010044535-A1 | Integrin antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044535-A1 | Integrin antagonists | ITGB3, VCAM1, ITGB2 | MAOA 4152/4885MAOB 1875/4885KMO 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.